Cardinal Health has upgraded its fiscal-year adjusted earnings guidance for 2026 to a range of $10.70 to $10.80 per share, an increase from the previous forecast of $10.15 to $10.35, following a strong third-quarter where it reported adjusted earnings of $3.17 per share and total revenues of $60.94 billion. The impressive results were driven by robust demand in the pharmaceutical and specialty solutions segment, contributing significantly to an 11.1% year-on-year revenue increase. Despite these positive developments, Cardinal Health's stock is down 4.3% over the past month, though analysts maintain an optimistic 'Strong Buy' outlook.
“Cardinal Health · raises · fiscal-year adjusted earnings guidance · for the second time this year”
“Cardinal Health, Inc. CAH · reported · third-quarter fiscal 2026 adjusted earnings per share (EPS) · $3.17”
“Cardinal Health, Inc. · saw · bottom line improvement · 35%”
“Cardinal Health · anticipates · adjusted EPS · between $10.70 and $10.80”
“Cardinal Health · returned · $1.0 billion · in share repurchases year to date”
“Pharma segment growth · was driven by · strong demand across specialty, generics, and consumer health”
“Specialty revenue · grew over · 20%”
“Cardinal Health · raises · fiscal-year adjusted earnings guidance · for the second time this year”
“Cardinal Health (CAH) · has topped consensus revenue estimates · two times · over the last four quarters”
“Cardinal Health · reported revenue · $60.94 billion · up 11.1% over the same period last year”
“Cardinal Health · EPS came in at · $3.17 · compared to $2.35 in the year-ago quarter”
“Cardinal Health · delivered an EPS surprise of · +13.22% · with the consensus EPS estimate being $2.80”
